<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945799</url>
  </required_header>
  <id_info>
    <org_study_id>KY2019-AHR-ZJU</org_study_id>
    <nct_id>NCT03945799</nct_id>
  </id_info>
  <brief_title>A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence</brief_title>
  <official_title>A Single Group, Open Label, Multi-center Clinical Study to Assess the Efficacy and Safety of Anlotinib in HCC Patients at High Risk of Post Surgery Recurrence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shulan (Hangzhou) Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin First Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the primary effects and safety of Anlotinib in HCC patients at high risk of post
      surgery recurrence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatocellular carcinoma is one of the most common malignant tumors in the world with high
      incidence and mortality. Recurrence of HCC is still a great challenge and threat to the
      patients after resection surgery. Anlotinib is a new, orally administered tyrosine kinase
      inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth
      factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. HCC
      patients who meet the eligibility criteria of this clinical trial will be administrated
      Anlotinib 12mg QD PO d1-14, 21 days per cycle. The disease free survival (DFS), overall
      survival (OS) and any adverse effect during the 8 cycles of Anlotinib treatment will be
      evaluated in order to assess the primary effects and safety of Anlotinib in HCC patients at
      high risk of post surgery recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>From randomization to recurrence of HCC or death (up to 1year)</time_frame>
    <description>The period from resection surgery to recurrence of HCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Up to 1year</time_frame>
    <description>Any adverse effects occur during the use of anlotinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>The survival rate in a year</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration Anlotinib and it should be continued until relapse of HCC or intolerable toxicity or patients withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib Hydrochloride</intervention_name>
    <description>Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.</description>
    <arm_group_label>Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No allergic history of Anlotinib

          -  18-75 years

          -  No history of severe arrhythmia or heart failure

          -  No history of severe ventilation dysfunction or severe pulmonary infection

          -  No acute or chronic renal failure, creatinine clearance &gt; 40 mL/min

          -  Liver function is normal: child-pugh grade A or grade B (≤7 points), total bilirubin ≤
             3.0 mg/dL, albumin ≥ 28 g/L, AST, ALT, ALP≤ 5 times of the upper limit of normal value

          -  Blood test: the absolute neutrophil count ≥ 1.5×10^9 /L, Hb ≥ 8.5 g/L, PLT ≥ 75×10^9
             /L (without blood transfusions and drug therapy 14 days before the screening)

          -  Blood coagulation function: INR≤2.3

          -  ECOG: 0-2

          -  Pathology: hepatocellular carcinoma

          -  Satisfy any of the following:

        A. portal vein, hepatic vein or bile duct carcinoma thrombus B. microvascular invasion
        (MVI) grade II (&gt; 5 MVI, or MVI occurs in the area more than 1 cm from the tumor) C. tumor
        number &gt;3 D. preoperative rupture of tumor or tumor invasion adjacent organs

          -  Patients participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients who have had or are currently complicated with other malignant tumors

          -  Recurrent hepatocellular carcinoma

          -  Patients who participated in other clinical trials within 1 month

          -  Patients with mental illness

          -  Patients treated with targeted drugs, immunotherapy (such as PD1 antibody), FOLFOX
             systemic chemotherapy or huaier granules after surgery

          -  Urine protein ≥ ++，and 24-hour urinary protein excretion＞1.0 g confirmed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiangguo Wang, PhD</last_name>
    <phone>(+86)15967123327</phone>
    <email>21118059@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Medical School of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangguo Wang, PhD</last_name>
      <phone>(+86)15967123327</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>May 9, 2019</last_update_submitted>
  <last_update_submitted_qc>May 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Xiao Xu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

